

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/PTO			Complete If Known		
		•		Application Number	10/511.666	
11	NFORMATION DIS	CLC	SURE	Filing Date	10/18/2004	
	TATEMENT BY AF			First Named Inventor	Milton L. Brown	
•				Art Unit	Unknown	
	(Use as many sheets as nec	essary	)	Examiner Name	Unknown	
Sheet	1	of	1	Attorney Docket Number	00769-07	

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
andais	NO.	Number-Kind Code <sup>2 (I known)</sup>	MIM-DD-1111	Applicant of Cited Document	Figures Appear
	1	<sup>US-</sup> 5,389,614	02/14/1995	König, et al.	Entire Document
	2	<sup>US-</sup> 4,258,054	03/24/1981	Sarges	Entire Document
		US-			
		US-			
		US-		,	
		US-			
	1	US-			
		US-	<del></del>		
		US-			
	<u> </u>	US-			
		US-			
		US-			
		US-			
	1	US-			
	<del>                                     </del>	US-			1

	FOREIGN PATENT DOCUMENTS										
Examiner Initials*	er Cite No.1 Foreign Patent Document  Country Code Number Kind Code (If known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear						
<del></del>			·			Т					
<del></del>											
						T					

Examiner	Date	- '
Signature	Considered	
0.6	 	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

10F	Under the Paperwork Reduction Act of 1995, no persons are required to re	Complete if Known			
, •	8	Application Number	10/511,666		
MAR	J 7 200 NEORMATION DISCLOSURE	Filing Date	October 18, 2004		
3		First Named Inventor	Milton L. Brown		
(Br.	SAATEMENT BY APPLICANT	Art Unit	1625		
191	(Use as many sheets as necessary)	Examiner Name	Unknown		
,	Sheet 1 of 2	Attorney Docket Number	00769-07		

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (7 known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
10	1	<sup>us-</sup> 5,463,125	10/31/2005	Guillermo C. Sandoval et al.	Entire Document
	2	<sup>US-</sup> 2,366,221	01/02/1945	James J. Spurlock	Entire Document
$\perp \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \!$	3	<sup>US-</sup> 2,256,231	10/17/1950	Henry R. Henze	Entire Document
Ø	4	us- 2002156016 A1	10/24/2002	Gerald Minuk	Entire Document
		US-	•		
		US-			
		09		***************************************	
		US-			
		US-			
		US-			
		US-		• • • • • • • • • • • • • • • • • • • •	
		US-			
	•	US-		1	
		US-			
		US-			
		US		1	
		US-			

j					FORE	IGN P	ATENT DOCU	JMENTS		
1	Examiner		Cite			Publication Date	Name of Patentee or	Pages, Columns, Lines,		
Į	Initiat	nitials* No.1				MM-DD-YYYY Applicant of Cited Document		Where Relevant Passages or Relevant Figures Appear	T⁰	
1		O	5	EP	0552631	A1	07/28/1993	Bayer AG	Entire Document	
ļ			6	EP	0076957	A1	04/20/1983	Bayer AG	Entire Document	
ļ			. 7	WO	99/41229	A1	08/19/1999	Guillermo Sandoval	Entire Document	
ļ			8	SU	447401				Entire Document	
Į	7		9	GB	980250		1/13/1965	Innothera	Entire Document	

Examiner Signature	n	Date Considered	5	7	215	<del>7.</del>
APVALABLED.						<u></u>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant, 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 08/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	form 1449B/PTO			Complete if Known				
				Application Number	10/511,666			
	RMATION D			Filing Date	October 18, 2004			
STATE	EMENT BY	APPLIC	CANT	First Named Inventor	Milton L. Brown			
				Art Unit	1625			
	Use as many sheets	as necessary)		Examiner Name	Unknown			
Sheet	2	of	2 ·	Attorney Docket Number	00769-07			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
74	K	DESPHANDE, R.N. et al., (1970), "Synthesis of Hydantoins of Pharmacological Interest," Indian Journal of Chemistry, Section B: Organic, Incl. Medicinal, Publications & Informatioins Directorate, New Delhi, IN, vol. 8, no. 11, pp. 1043-1044.	
	L	GALVEZ, E. et al., (1983), "Synthesis and Structural Studey of Cyclopentane, Indene and Flourene Spiro-derivatives," Journal of Heterocyclic Chemistry, Heterocorporation. Provo, US, vol. 20, no. 1, pp. 13-16.	
	M	SARGES, R. et al., (1987), "Spiro Hydantoin Aldose Redutase Inhibitors," Journal of Medicinal Chemistry, vol. 31, no. 1, pp. 230-242.	•
1	N	DUPRIEST, M.T. et al., (1991), "Spiro[fluoreneisothiazolidin]one Dioxides: New Aldose Redutase and L-Hexonate dehydrogenase Inhibitors," Journal of Medicinal Chemistry, vol. 34, no. 11, pp. 3229-3234.	
			**********
			!
			\

	,	
Examiner Signature	Date Considered	8 MM

<sup>&</sup>quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (07-05)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are equired to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	or form 1449B/PTO	3 MAN	A YOUR THE		Complete if Known	
	RMATION D	1 Branch	<b>3</b>	Application Number	10/511,666	
				Filing Date	October 18, 2004	
STAT	EMENT BY	APPLI	ICANT		Milton L. Brown	<del>.</del>
				Art Unit	1625	,
····	(Use as many sheets a	s necessary	) 	Examiner Name	Unknown	
Sheet	1 1	l of	_	Attorney Docket Number	00700 07	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
NY	A	ABDUL, M. et al., (2001), "Inhibition by Anticonvulsants of Prostate-specifice Antigen and Interleukin-6 Secretion by Human Prostate Cancer Cells," Anticancer Research, vol. 21, pp. 2045-2048.				
	В.	MEZA-TOLEDO, S.E. et al., (1995), "Stereoselective Anticonvulsant Activity of the Enantiomers of (.+)-2-Hydroxy-2-phenylbutyramide," Arzneimittel Forschung. Drug Research, vol. 45, pp. 756-759.				
	С	MEZA-TOLEDO, S.E. et al., (1990), "A New Homologous Series of Anticonvulsants: Phenyl Alcohol Amides," Arzneimittel Forschung. Drug Research, vol. 40, pp. 1289-1291.	••••••			
	D	WILIMOWSKI, M. et al., (1970), "Pharmacologic Properties of Derivatives of 3-Phenyl-3-Hydroxyglutaric Acid," Archivum Immunologiae et Therapiae Experimentalis, vol. 18, pp.270-279.	**********			
	Е	BARRIO, J. et al., (1971), "5-Cyclohexylmethyl-5-arylhydantoins," Journal of Medicinal Chemistry, vol. 14, no. 9, p. 898.	***********			
	F	BROWN, M.L. et al., (1999), "Comparative Molecular Field Analysis of Hydantoin Binding to the Neuronal Voltage-Dependent Sodium Channel," J. Med. Chem., vol. 42, pp. 1537-1545.	·			
	G	KNABE, J. et al., (1997), "Razemate und Enantiomere basisch substituierter 5-Phenylhydantoine, Synthese und antiarrhythmische Wirkung, Racemates and enantiomers of basic substituted 5-phenylhydantoins, synthesis and antiarrhythmic activity," Pharmazie, Die, Gopvi Verlag, Eschborn, De, vol. 52, pp. 912-919.				
	Н	CASAGRANDE, C. et al., (1974), "Synthesis and antiarrhythmic activity of 5,5-disubstituted-3-aminoalkylhydantoins and some heterocyclic and noncyclid analogues," Farmaco, Edizione Scientifica, Societa Chemica Italiana, Pavia IT, vol. 29, no. 10, pp. 757-785.	<del></del>			
	I	BROUILLETTE, W.J. et al., (1990), "Sodium channel binding and anticonvulsant activities of hydantoins containing conformationally constrained 5-phenyl substituents," J. of Pharmaceutical Sciences, Am. Pharmaceutical Assoc. Washington, US, vol. 79, no. 10, pp. 871-874.				
	, 1	KADAM, A.N. et al., (1978), "Synthesis of gamma-(5-arylhydantoin-5)-butyric acids," J. of the Indian Chemical Society, Calcutta, IN, vol. 51, no. 1, pp. 107-108.	**********			

Examiner Signature	M	Date Considered	8/2/m

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/511,666

Filing Date October 18, 2004

First Named Inventor Milton L. Brown

Art Unit 1625

Examiner Name Unknown

(Use as many sheets as necessary)

Substitute for form 1449A/PTO

Sheet 2 of 2 Attorney Docket Number 00769-07

2006

		- · · · · · · · · · · · · · · · · · · ·	U.S. PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Number-Kind Code <sup>2 of known)</sup>			Figures Appear	
		US-				
		US- ,				
		76				
		US-				
		∪s→	9.	·		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS									
Examiner Cito Initials* No.		Cite	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		140.	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (if known)		۳				
14	2]	.10	EP	0006407	A1	1/9/1980	Nippon Zoki Pharm.	Entire Document	
		11	wo	02/083133	A1	10/24/2002	Univ of Va Patent Found.	Entire Document	
	_	12	GB	1566171		4/30/1980	Pfizer, Inc.	Entire Document	
<u> </u>		13.	EP	0115133	<u>A1</u>	8/8/1984	Pfizer, Inc.	Entire Document	
<u> </u>		14	wo	01/45704	A1	6/28/2001	Merck & Co.	Entire Document	

Examiner		Date	
01			$\mathcal{L}(\mathcal{L}(\mathcal{L}))$
Signature		Considered	$X \mid \mathcal{L} \mid \mathcal{U} \mid$
	1/1/1/	Considered	0 / - / + /
	7/1/-		• / / /

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.